Cargando…

Comparison of Two Strategies for Prophylactic Donor Lymphocyte Infusion in Patients With Refractory/Relapsed Acute Leukemia

Prophylactic donor lymphocyte infusion (pDLI) could reduce relapse in patients with refractory/relapsed acute leukemia (RRAL) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT), but optimal timing of pDLI remains uncertain. We compared the outcomes of two strategies for pDLI b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Qiongqiong, Fan, Zhiping, Huang, Fen, Xu, Na, Nie, Danian, Lin, Dongjun, Guo, Ziwen, Shi, Pengcheng, Wang, Zhixiang, Jiang, Ling, Sun, Jing, Jiang, Zujun, Liu, Qifa, Xuan, Li
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7966710/ https://www.ncbi.nlm.nih.gov/pubmed/33747904 http://dx.doi.org/10.3389/fonc.2021.554503

Ejemplares similares

Sequential intensified conditioning followed by prophylactic DLI could reduce relapse of refractory acute leukemia after allo-HSCT
por: Xuan, Li, et al.
Publicado: (2016)

Haploidentical versus HLA-matched sibling transplantation for refractory acute leukemia undergoing sequential intensified conditioning followed by DLI: an analysis from two prospective data
por: Yu, Sijian, et al.
Publicado: (2020)

Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial
por: Jin, Hua, et al.
Publicado: (2023)

Haploidentical transplantation has a superior graft-versus-leukemia effect than HLA-matched sibling transplantation for Ph– high-risk B-cell acute lymphoblastic leukemia
por: Fan, Menglin, et al.
Publicado: (2022)

Nonengraftment donor lymphocyte infusions for refractory acute myeloid leukemia
por: Reagan, J L, et al.
Publicado: (2015)

The efficacy of mesenchymal stem cells in bronchiolitis obliterans syndrome after allogeneic HSCT: A multicenter prospective cohort study
por: Chen, Shan, et al.
Publicado: (2019)

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
por: Gagelmann, Nico, et al.
Publicado: (2023)

Haploidentical related donor vs matched sibling donor allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome aged over 50 years: A single‐center retrospective study
por: Huang, Jiafu, et al.
Publicado: (2020)

An observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia
por: Ma, Jun, et al.
Publicado: (2018)

Differential effects of donor lymphocyte infusion upon treatment response and GVHD according to relapse level and donor sources in patients with myelodysplastic syndrome
por: Park, Silvia, et al.
Publicado: (2021)

The graft-versus-leukemia effect of prophylactic donor lymphocyte infusions after allogeneic stem cell transplantation is equally effective in relapse prevention but safer compared to spontaneous graft-versus-host disease
por: Stadler, Michael, et al.
Publicado: (2023)

Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies
por: Gao, Xiao-Ning, et al.
Publicado: (2018)

Intra-bone donor lymphocyte infusion at relapse: clinical outcome is associated with presence of CD8+ cells in the marrow
por: Lange, Andrzej, et al.
Publicado: (2019)

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering
por: Ye, Yishan, et al.
Publicado: (2022)

Autoimmune hematological diseases following haploidentical donor hematopoietic stem cell transplant compared with matched sibling and unrelated donor
por: Lv, Weiran, et al.
Publicado: (2017)

Prophylactic Heme Arginate Infusion for Acute Intermittent Porphyria
por: Kuo, Hung-Chou, et al.
Publicado: (2021)

Understanding anti-leukemia responses to donor lymphocyte infusion
por: Bachireddy, Pavan, et al.
Publicado: (2014)

Combination of Donor Lymphocyte Infusion and Blinatumomab for B-Cell Lymphoblastic Lymphoma Relapse after Allogeneic Stem-Cell Transplantation
por: Mori, Jinichi, et al.
Publicado: (2023)

Management of relapsed/refractory Chronic Lymphocytic Leukemia
por: Woyach, Jennifer A.
Publicado: (2022)

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023)

Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia
por: Schmid, Christoph, et al.
Publicado: (2021)

Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients
por: van der Zouwen, Boris, et al.
Publicado: (2023)

Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors
por: Liberatore, Carmine, et al.
Publicado: (2022)

The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients
por: Jiang, Xuejie, et al.
Publicado: (2015)

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
por: Hall, Erin M, et al.
Publicado: (2021)

Repeated Infusions of Brexucabtagene-autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
por: Aydilek, Enver, et al.
Publicado: (2023)

Co-transplantation of mesenchymal stem cells makes haploidentical HSCT a potential comparable therapy with matched sibling donor HSCT for patients with severe aplastic anemia
por: Liu, Zenghui, et al.
Publicado: (2020)

Risk-adapted donor lymphocyte infusion based on chimerism and donor source in pediatric leukemia
por: Rujkijyanont, P, et al.
Publicado: (2013)

Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia
por: Shustik, C., et al.
Publicado: (2017)

Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
Publicado: (2021)

Spectral flow cytometry cluster analysis of therapeutic donor lymphocyte infusions identifies T cell subsets associated with outcome in patients with AML relapse
por: Odak, Ivan, et al.
Publicado: (2022)

A Phase I Trial of Allogeneic γδ T Lymphocytes From Haploidentical Donors in Patients With Refractory or Relapsed Acute Myeloid Leukemia
por: Vydra, Jan, et al.
Publicado: (2023)

Granulocytic sarcoma as isolated extramedullary relapse after donor lymphocyte infusion in a patient with CML who relapsed after allogeneic bone marrow transplantation: a case report.
por: Lee, J. J., et al.
Publicado: (1998)

Treatment of relapsed acute leukemia by Ara C plus donor lymphocyte infusion using CD34＋ cells reserved at the time of allogeneic transplantation
por: YJ, Lee, et al.
Publicado: (2020)

Ofatumumab and Complement Replacement in Relapsed/Refractory Chronic Lymphocytic Leukemia
por: Tuscano, Joseph, et al.
Publicado: (2020)

Indirect comparisons of efficacy of zanubrutinib versus orelabrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma or relapsed or refractory mantle cell lymphoma
por: Song, Yuqin, et al.
Publicado: (2023)

Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse
por: Shapiro, Roman M., et al.
Publicado: (2022)

Donor lymphocyte infusions in adolescents and young adults for control of advanced pediatric sarcoma
por: Schober, Sebastian J., et al.
Publicado: (2018)

Graft‐versus‐mastocytosis effect after donor lymphocyte infusion: Proof of principle
por: Hägglund, Hans, et al.
Publicado: (2020)

Harnessing allogeneic NK cells: improving outcomes with tailored donor lymphocyte infusion
por: McCurdy, Shannon R.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6t86k9aq1810bs30pjabktv3mc